|
|
|
|
Troikaa Pharma set to get US patent
Tags: Gujarat-based fast growing healthcare company, Troikaa Pharmaceuticals Troikaa Pharmaceuticals, a Gujarat based fast growing healthcare company, is likely to get US patent for its novel drug delivery form of Diclofenac injections-Dyanapar AQ....
|
|
|
Topical Diclofenac Effective for Elderly and Younger Patients With Hand Osteoarthritis: Presented at AAPM
-- Topical diclofenac sodium 1% gel significantly improves pain, function, and disease status in patients of all ages with hand osteoarthritis (OA), according to findings presented here at the 26th annual meeting of the American Academy of Pain Medicine ...
|
|
|
FDA Accepts Javelin Pharmaceuticals' Dyloject(TM) New Drug Application for Formal Review
NDA for Management of Acute Moderate-to-Severe Pain Includes Data from 16 Clinical Studies CAMBRIDGE, MA, USA | February 02, 2010 | Javelin Pharmaceuticals, Inc.(NYSE Amex: JAV), a leading developer and marketer of specialty pharmaceutical products for pain...
|
|
|
Topical Diclofenac Effective for Elderly and Younger Patients With Hand Osteoarthritis: Presented at AAPM
-- Topical diclofenac sodium 1% gel significantly improves pain, function, and disease status in patients of all ages with hand osteoarthritis (OA), according to findings presented here at the 26th annual meeting of the American Academy of Pain Medicine ...
|
|
|
FDA OKs Javelin Pharmaceuticals' Dyloject NDA for Formal Review
Javelin Pharmaceuticals, Inc., a developer and marketer of specialty pharmaceutical products for pain management, said that its New Drug Application (NDA) submitted on December 2, to the US Food and Drug Administration (FDA) for its investigational product...
|
|
|
FDA OKs Javelin Pharmaceuticals' Dyloject NDA for Formal Review
Javelin Pharmaceuticals, Inc., a developer and marketer of specialty pharmaceutical products for pain management, said that its New Drug Application (NDA) submitted on December 2, to the US Food and Drug Administration (FDA) for its investigational product...
|
|
|
FDA OKs Javelin Pharmaceuticals' Dyloject NDA for Formal Review -...
Company: Javelin Pharmaceuticals Inc (JAV) Javelin Pharmaceuticals, Inc., a developer and marketer of specialty pharmaceutical products for pain management, said that its New Drug Application (NDA) submitted on December 2, to the US Food and Drug Administration...
|
|
|
Troikaa Pharma to enhance marketing capabilities
Ahmedabad based mid sized pharma company Troikaa Pharmaceuticals is enlarging its marketing presence both in domestic and international markets.The company has planned to open two new divisions in India for pain management and diabetes by end April 2010.
|
|
|
Dasatinib Therapy: Research from Scripps Research Institute in the area of dasatinib therapy published
Today's Medical & Research News Dasatinib Therapy Research from Scripps Research Institute in the area of dasatinib therapy published February 5th, 2010 Printer-Friendly Version City:Jupiter State:FL Country:United States Dasatinib Therapy Acetaminophen...
|
|
|
Can Ulcers Lead to Cancer?
Neena S.Abraham, a gastroenterologist at the Michael E. DeBakey V.A. Medical Center and associate professor of medicine at the Baylor College of Medicine in Houston, recently took readers questions about ulcers, a potentially life-threatening condition...
|
|
|
FDA Accepts Javelin PharmaceuticalsEUR Dyloject New Drug Application For Formal Review
Javelin Pharmaceuticals, Inc.(NYSE Amex: JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration...
|
|
|
FDA Accepts Javelin Pharmaceuticals' Dyloject New Drug Application for Formal Review
NDA for Management of Acute Moderate-to-Severe Pain Includes Data from 16 Clinical Studies CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 2, 2010 - Javelin Pharmaceuticals, Inc.(NYSE Amex: JAV), a leading developer and marketer of specialty pharmaceutical products...
|
|
|
NHS blunder for allergy Mum
A YOUNG mum who has battled severe allergies for 10 years says her doctor prescribed her medicine that would have hospitalised her - due to a paperwork blunder.Tanya Tingley, 32, claims her GP's surgery has not yet updated her medical history, despite the...
|
|
|
FDA Accepts Javelin Pharmaceuticals Dyloject New Drug Application for Formal Review
Javelin Pharmaceuticals, Inc.(NYSE Amex: JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration...
|
|
|
Javelin Pharmaceuticals' NDA for Dyloject Injection accepted for formal review
Javelin Pharmaceuticals, Inc.(NYSE Amex: JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration...
|
|
|
POPE: Postoperative therapy with diclofenac yielded no effect on size of pericardial effusion
Treatment with diclofenac neither reduced the size of pericardial effusions nor decreased the rate of tamponade in patients recovering from surgery, study results suggested.Researchers for the POPE study enrolled 196 patients at high risk for tamponade...
|
|
|
Diclofenac sodium topical solution (Pennsaid): Nonsteroidal anti-inflammatory topical solution approved for chronic management of knee osteoarthritis
Diclofenac sodium 1.5% w/w topical solution was approved by FDA on November 2009, to treat the signs and symptoms of osteoarthritis of the knee.The active ingredient, diclofenac sodium, is a nonsteroidal antiinflammatory drug. Diclofenac...
|
|
|
Dr. Andy: Arthritis medications can cause intestinal bleeding
Like many of us, John found great relief for his arthritis by taking diclofenac.Used daily by many Americans, non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used medications in the United States. While diclofenac may...
|
|
|
FDA Accepts Javelin Pharmaceuticals' Dyloject New Drug Application for Formal Review
NDA for Management of Acute Moderate-to-Severe Pain Includes Data from 16 Clinical Studies CAMBRIDGE, Mass.Acceptance by the FDA of Javelin's comprehensive NDA submission for Dyloject marks a significant regulatory milestone towards our goal of...
|
|
|
POPE published: Avoid NSAIDs for asymptomatic pericardial effusions
Diclofenac does not reduce pericardial effusions, according to the POPE study.POPE published: Avoid NSAIDs for asymptomatic pericardial effusions.
|
|
|
FDA Accepts Javelin Pharmaceuticals Dyloject New Drug Application for Formal Review
CAMBRIDGE, Mass.-- (BUSINESS WIRE) -- Javelin Pharmaceuticals, Inc.(NYSE Amex: JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009...
|
|
|
Study Doesn't Support Drug for Pericardial Effusion
In patients with pericardial effusion following heart surgery, the use of the nonsteroidal anti-inflammatory drug diclofenac doesn't reduce the size of the effusions or lower the risk of late cardiac tamponade, according to research Study Doesn't Support...
|
|
|
FDA Accepts Javelin Pharmaceuticals Dyloject New Drug Application for Formal Review
Javelin Pharmaceuticals, Inc.Rating: Related Stocks: Text Size: Javelin Pharmaceuticals, Inc. (NYSE Amex: JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA)...
|
|
|
FDA Accepts Javelin Pharmaceuticals Dyloject„ New Drug Application for Formal Review
Javelin Pharmaceuticals, Inc.(NYSE Amex: JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration...
|
|
|
FDA Accepts Javelin Pharmaceuticals Dyloject New Drug Application for Formal Review
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc.(NYSE Amex: JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to...
|
